Plain-English translation of NCT07275970 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our PTSD research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether psilocybin-containing mushrooms can help treat PTSD in adults. Researchers will give participants a single dose of psilocybin mushrooms in chocolate form and carefully monitor their safety and whether the treatment helps reduce PTSD symptoms. The study will include up to 24 people and collect detailed information about how the medication affects their body and mental health.
Current treatments for PTSD don't work well enough for everyone, and some people don't respond to traditional therapy or medications. This study is exploring whether this medication might offer a new option for people suffering from PTSD.
You would visit the research site to take a single dose of psilocybin mushrooms in chocolate form. The researchers will monitor your safety and symptoms before, during, and after the experience. You'll also need to wear a health-tracking device daily and complete questionnaires about your symptoms and quality of life throughout the study. The study involves screening visits, the treatment day itself, and follow-up visits to check on your progress and safety.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Scottsdale Research Institute
Enrollment target
~24 participants
Started
March 2026
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.